Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:

NCT ID: NCT05165706 Recruiting - Obesity Clinical Trials

Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance

Start date: January 31, 2019
Phase: N/A
Study type: Interventional

This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. Additionally, direct insulin sensitivity testing, and radiological measurement of visceral fat and intrahepatic fat content is measured at three timepoints to correlate clinical indices with cellular changes.

NCT ID: NCT05084404 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease

Start date: October 29, 2021
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension

NCT ID: NCT05083390 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Norursodeoxycholic Acid vs. Placebo in NASH

Start date: July 8, 2019
Phase: Phase 2
Study type: Interventional

This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with either 1500 mg/d or 1000 mg/d norUDCA tablets vs. placebo tablets for the treatment of NASH.

NCT ID: NCT05029583 Recruiting - Type 2 Diabetes Clinical Trials

Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)

Start date: August 11, 2021
Phase: N/A
Study type: Interventional

The study is stratified cluster randomized trial. The study population will include adults with T2D and presumed NASH.

NCT ID: NCT05012423 Recruiting - Osteoarthritis Clinical Trials

FTIH Study of ECC0509 in Healthy Volunteers

Start date: July 7, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.

NCT ID: NCT05011305 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

NASH
Start date: August 18, 2021
Phase: Phase 2
Study type: Interventional

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis

NCT ID: NCT04971785 Active, not recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

WAYFIND
Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.

NCT ID: NCT04944992 Completed - Clinical trials for Nonalcoholic Steatohepatitis

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Start date: August 4, 2021
Phase: Phase 2
Study type: Interventional

The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.

NCT ID: NCT04887038 Completed - Clinical trials for Nonalcoholic Steatohepatitis

First-in-Human Study of SRT-015 in Healthy Subjects.

Start date: May 3, 2021
Phase: Phase 1
Study type: Interventional

This is phase 1 first-in-human trial evaluating SRT-015 to assess safety, tolerability and pharmacokinetics. This study will be conducted in 3 parts - SAD, MAD and Food Effect with target of 96 healthy volunteers. This will be a single center, Phase 1, randomized, double-blind, placebo controlled, SAD and MAD study of dose escalation cohorts evaluating administration of SRT-015 or placebo. Additionally, PK will be assessed in fed and fasting states.

NCT ID: NCT04828551 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Noninvasive Biomarkers of Metabolic Liver Disease 1.1

Start date: March 18, 2021
Phase: N/A
Study type: Interventional

NIMBLE is a comprehensive collaborative effort to standardize, compare, validate, and advance the regulatory qualification of imaging and circulating biomarkers to diagnose and stage nonalcoholic steatohepatitis (NASH), and to predict and assess response to therapeutic intervention (https://fnih.org/what-we-do/biomarkers-consortium/programs/nimble). This study focuses on estimating the repeatability and reproducibility of ultrasound elastography-based biomarkers across a range of fibrosis stages.